ClinicalTrials.gg
CompletedNCT03410693FORT-1Updated Sep 28, 2022Results posted

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

A Phase 2/3 interventional study of Rogaratinib (BAY1163877) and Chemotherapy in Carcinoma, Transitional Cell, sponsored by Bayer. Completed at 161 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-28.

Sponsored by Bayer · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Carcinoma, Transitional Cell with a site in Japan — 12 open to participants now, 15 under way, 5 of them phase 3. Carcinoma, Transitional Cell · Japan.

Enrollment
18th of 35
175 · median 175
Started
2018
with 2 others
Phase 2/3
2 of 38
1 open now
Registered
12th of 38
by date
Lead sponsor
2 of 38
Bayer

Among the 38 studies in Carcinoma, Transitional Cell with a site in Japan, this one is the 18th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 2/3, and was the 12th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

12 of the 38 studies in Carcinoma, Transitional Cell with a site in Japan are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Carcinoma, Transitional Cell with a site in Japan, or all of them as a file.
02

Study summary

This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy.

The primary objective is to demonstrate the superiority of rogaratinib over chemotherapy in terms of objective response rate (before: overall survivial) of urothelial carcinoma patients with FGFR positive tumors.

At randomization, patients will have locally advanced or metastatic urothelial carcinoma and have received at least one prior platinum-containing chemotherapy regimen. Only patients with FGFR1 or 3 positive tumors can be randomized into the study. Archival tumor tissue is adequate for testing of FGFR1 and 3 mRNA expressions, which will be determined centrally using an RNA in situ hybridization (RNA-ISH) test. Approximately 42 % of UC patients with locally advanced or metastatic UC are identified as FGFR-positive by the RNA-ISH cut-off applied.

03

Conditions studied

  • Carcinoma, Transitional Cell

Keywords

  • Urothelial carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Existence of archival or fresh for FGFR testing. Mandatory FGFR testing of patients will be performed prior to start of screening. The timing of the FGFR test is at the discretion of the investigator. Investigators should ensure all patients will be eligible in terms of disease status and .
  • Documented urothelial carcinoma (transitional cell carcinoma) including urinary bladder, renal pelvis, ureters, urethra meeting all of the following criteria

    • confirmed (Patients with mixed histologies are required to have a dominant transitional cell pattern.)
    • Locally advanced (T4, any N; or any T, N 2-3) or disease (any T, any N and M1). Locally advanced bladder cancer must be unresectable i.e. invading the pelvic or abdominal wall (stage T4b) or presenting with bulky nodal disease (N2-3).
  • (Eastern Cooperative Oncology Group) Performance Status of 0 or 1
  • Disease progression during or following treatment with at least one platinum-containing regimen (patients should have been treated for at least 2 cycles). In patients who received prior / neoadjuvant platinum-containing chemotherapy, progression had to occur within 12 months of treatment.
  • High FGFR1 or 3 mRNA expression levels in archival or fresh tumor biopsy specimen quantified as outlined in the lab manual
  • At least 1 according to (RECIST v.1.1) in contrast enhanced (unless ) CT or MRI

Exclusion criteria

Exclusion Criteria:

  • Previous or concurrent cancer except

    • cervical carcinoma in situ
    • treated basal-cell or squamous cell skin carcinoma
    • any cancer curatively treated > 3 years before randomization
    • curatively treated incidental prostate cancer (T1/T2a)
  • Ongoing or previous treatment with anti-FGFR directed therapies (e.g. receptor tyrosine kinase inhibitors including rogaratinib or FGFR-specific antibodies) or with taxanes or vinflunine
  • More than two prior lines of systemic anti-cancer therapy for urothelial carcinoma given for advanced unresectable/ disease
  • Ongoing or previous anti-cancer treatment within 4 weeks before randomization.
  • Unresolved toxicity higher than National Cancer Institute's , version 4.03 (CTCAE v.4.03) Grade 1 attributed to any prior therapy/ procedure excluding alopecia, anemia and/ or hypothyroidism
  • History or current condition of an uncontrolled cardiovascular disease including any of the following conditions:

    • Congestive heart failure (CHF) (New York Heart Association) > Class 2
    • Unstable angina (symptoms of angina at rest) or new-onset angina (within last 3 months before randomization)
    • Myocardial infarction (MI) within past 6 months before randomization
    • Unstable cardiac arrhythmias requiring anti-arrhythmic therapy. Patients with arrhythmia under control with anti-arrhythmic therapy such as beta-blockers or digoxin are eligible.
  • Arterial or venous thrombotic events or embolic events such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism within 3 months before randomization
  • Current evidence of endocrine alteration of calcium phosphate homeostasis (e.g. parathyroid disorder, history of parathyroidectomy, tumor lysis, tumoral calcinosis, paraneoplastic hypercalcemia)
  • Current diagnosis of any retinal detachment, retinal pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion
  • Any hemorrhage / bleeding event ≥ CTCAE v.4.03 Grade 3 within 4 weeks before randomization
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Rogaratinib

    Rogaratinib treatment study arm, comprising 1. Pre-treatment period, including FGFR testing and screening, 2. Treatment period, and 3. Follow-up period, including active follow-up and long-term follow-up. Patients will be considered "on study" during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered "off study".

    Drug: Rogaratinib (BAY1163877)

  • Active comparator
    Chemotherapy

    Chemotherapy treatment study arm, comprising 1. Pre-treatment period, including FGFR testing and screening, 2. Treatment period, and 3. Follow-up period, including active follow-up and long-term follow-up. Patients will be considered "on study" during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered "off study".

    Drug: Chemotherapy

Interventions

  • Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously

  • DrugChemotherapy

    Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) - Central Assessment

    ORR is defined as the percentage of participants with complete response (CR) or partial response (PR). participants for whom overall best response is not CR or PR, as well as participants without any post-baseline tumor assessment will be considered non-responders.

    Time frame: From start of treatment up to end of active follow-up, approximately 29 months

Secondary outcomes

  1. Disease-control Rate (DCR) - Central Assessment

    DCR was defined as the percentage of participants whose overall best response was not a progressive disease (i.e., CR, PR, stable disease \[SD\] or Non CR/Non PD).

    Time frame: From start of treatment till end of active follow-up, approximately 29 months

  2. Progression-free Survival (PFS) - Central Assessment

    Progression free survival (PFS) was defined as the time (days) from randomization to date of first observed disease progression (radiological or clinical assessment or both) or death due to any cause (if death occurred before progression was documented).

    Time frame: From start of treatment till end of active follow-up, approximately 29 months

  3. Duration of Response (DOR) - Central Assessment

    DOR (for patients with PR and CR only) was defined as the time from the first documented objective response of PR or CR, whichever was noted earlier, to disease progression (including symptomatic deterioration) or death, whichever was earlier

    Time frame: From start of treatment till end of active follow-up, approximately 29 months

  4. Number of Participants With Treatment Emergent Adverse Events

    A treatment-emergent event was defined as any event arising or worsening after the start of study drug administration until 30 days after the last administration of study treatment

    Time frame: From start of treatment up to 30 days after the last administration of study treatment, approximately 29 months

07

Results

Posted Dec 29, 2021

Participant flow

This study enrolled participants at 111centers in 28 countries from 31 MAY 2018 (first participant first visit) to 27 OCT 2020 (last participant last visit).

Participant flow — Overall Study
MilestoneRogaratinib (BAY1163877)_Overall PopulationChemotherapy_Overall Population
Started8788
Started treatment8682
Active follow-up performed6156
Entered long term follow-up5669
Completed00
Not completed8788
Withdrew: Disc trt: withdrawal by participant64
Withdrew: Disc trt: lost to follow up01
Withdrew: Disc trt: radiological progression5850
Withdrew: Disc trt: other10
Withdrew: Study drug never administered16
Withdrew: Discontinued (disc) treatment (trt): death64
Withdrew: Disc trt: adverse event (ae)139
Withdrew: Disc trt: physician decision05
Withdrew: Disc trt: clinical progression15
Withdrew: Disc trt:ae not asso. w/ clinical disease progress14

Outcome measures

PrimaryObjective Response Rate (ORR) - Central Assessment

ORR is defined as the percentage of participants with complete response (CR) or partial response (PR). participants for whom overall best response is not CR or PR, as well as participants without any post-baseline tumor assessment will be considered non-responders.

Time frame:
From start of treatment up to end of active follow-up, approximately 29 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) - Central Assessment
percentage of participantsRogaratinib (BAY1163877)_Overall PopulationChemotherapy_Overall PopulationRogaratinib_WT PopulationChemotherapy_WT Population
Objective Response Rate (ORR) - Central Assessment19.5 (11.8 to 29.4)21.6 (13.5 to 31.6)19.4 (10.4 to 31.4)23.8 (14.0 to 36.2)
Statistical analysis
  • Rogaratinib (BAY1163877)_Overall Population vs Chemotherapy_Overall Population · Fisher Exact · p = =0.6991 · Orr difference (r-c): -2.1 · 95% CI -14.0 to 9.9
  • Rogaratinib_WT Population vs Chemotherapy_WT Population · Fisher Exact · p = =0.7944 · Orr difference (r - c): -4.5 · 95% CI -18.9 to 9.9
SecondaryDisease-control Rate (DCR) - Central Assessment

DCR was defined as the percentage of participants whose overall best response was not a progressive disease (i.e., CR, PR, stable disease \[SD\] or Non CR/Non PD).

Time frame:
From start of treatment till end of active follow-up, approximately 29 months
Reported as:
Number · percentage of participants
Disease-control Rate (DCR) - Central Assessment
percentage of participantsRogaratinib (BAY1163877)_Overall PopulationChemotherapy_Overall PopulationRogaratinib_WT PopulationChemotherapy_WT Population
Disease-control Rate (DCR) - Central Assessment50.6 (39.6 to 61.5)55.7 (44.7 to 66.3)53.2 (40.1 to 66.0)63.5 (50.4 to 75.3)
Statistical analysis
  • Rogaratinib (BAY1163877)_Overall Population vs Chemotherapy_Overall Population · Fisher Exact · p = =0.7962 · Dcr difference (r-c): -5.1 · 95% CI -19.9 to 9.7
  • Rogaratinib_WT Population vs Chemotherapy_WT Population · Fisher Exact · p = =0.9109 · Dcr difference (r-c): -10.3 · 95% CI -27.5 to 6.9
SecondaryProgression-free Survival (PFS) - Central Assessment

Progression free survival (PFS) was defined as the time (days) from randomization to date of first observed disease progression (radiological or clinical assessment or both) or death due to any cause (if death occurred before progression was documented).

Time frame:
From start of treatment till end of active follow-up, approximately 29 months
Reported as:
Median · months
Progression-free Survival (PFS) - Central Assessment
monthsRogaratinib (BAY1163877)_Overall PopulationChemotherapy_Overall PopulationRogaratinib_WT PopulationChemotherapy_WT Population
Progression-free Survival (PFS) - Central Assessment2.7 (1.6 to 4.6)3.2 (2.7 to 4.4)2.8 (2.6 to 5.1)4.0 (2.8 to 6.1)
Statistical analysis
  • Rogaratinib (BAY1163877)_Overall Population vs Chemotherapy_Overall Population · Log Rank · p = = 0.8672 · Hazard ratio (hr): 1.226 · 95% CI 0.853 to 1.762
  • Rogaratinib_WT Population vs Chemotherapy_WT Population · Log Rank · p = 0.9171 · Hazard ratio (hr): 1.341 · 95% CI 0.880 to 2.043
SecondaryDuration of Response (DOR) - Central Assessment

DOR (for patients with PR and CR only) was defined as the time from the first documented objective response of PR or CR, whichever was noted earlier, to disease progression (including symptomatic deterioration) or death, whichever was earlier

Time frame:
From start of treatment till end of active follow-up, approximately 29 months
Reported as:
Median · months
Duration of Response (DOR) - Central Assessment
monthsRogaratinib (BAY1163877)_Overall PopulationChemotherapy_Overall PopulationRogaratinib_WT PopulationChemotherapy_WT Population
Duration of Response (DOR) - Central Assessment4.9 (2.2 to 7.0)5.8 (3.5 to 7.7)5.1 (1.5 to 9.2)7.0 (2.7 to 8.4)
SecondaryNumber of Participants With Treatment Emergent Adverse Events

A treatment-emergent event was defined as any event arising or worsening after the start of study drug administration until 30 days after the last administration of study treatment

Time frame:
From start of treatment up to 30 days after the last administration of study treatment, approximately 29 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsRogaratinib (BAY1163877)Chemotherapy
Any TEAE8682
Any drug related TEAE8176

Adverse events

Collected over Approximately 29 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rogaratinib (BAY1163877)47/86 (54.7%)39/86 (45.3%)85/86 (98.8%)
Chemotherapy45/82 (54.9%)33/82 (40.2%)77/82 (93.9%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventRogaratinib (BAY1163877)Chemotherapy
Febrile neutropeniaBlood and lymphatic system disorders0/864/82
NeutropeniaBlood and lymphatic system disorders0/864/82
Urinary tract infectionInfections and infestations1/864/82
DeathGeneral disorders4/862/82
General physical health deteriorationGeneral disorders4/861/82
SepsisInfections and infestations0/863/82
HaematuriaRenal and urinary disorders1/863/82
Abdominal painGastrointestinal disorders3/860/82
Acute kidney injuryRenal and urinary disorders3/862/82
DyspnoeaRespiratory, thoracic and mediastinal disorders3/860/82
Most frequent other events
Showing 10 of 57
Most frequent other events
EventRogaratinib (BAY1163877)Chemotherapy
DiarrhoeaGastrointestinal disorders48/8618/82
HyperphosphataemiaMetabolism and nutrition disorders39/860/82
Decreased appetiteMetabolism and nutrition disorders36/8621/82
ConstipationGastrointestinal disorders25/8629/82
AnaemiaBlood and lymphatic system disorders11/8628/82
FatigueGeneral disorders21/8628/82
NauseaGastrointestinal disorders27/8620/82
AlopeciaSkin and subcutaneous tissue disorders20/8624/82
AstheniaGeneral disorders25/8619/82
NeutropeniaBlood and lymphatic system disorders3/8619/82

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rogaratinib (BAY1163877)_Overall PopulationChemotherapy_Overall PopulationTotal
Mean67.7 ± 8.366.4 ± 10.367.0 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Rogaratinib (BAY1163877)_Overall PopulationChemotherapy_Overall PopulationTotal
Female7570145
Male121830
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rogaratinib (BAY1163877)_Overall PopulationChemotherapy_Overall PopulationTotal
Hispanic or Latino101
Not Hispanic or Latino7678154
Unknown or Not Reported101020
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rogaratinib (BAY1163877)_Overall PopulationChemotherapy_Overall PopulationTotal
American Indian or Alaska Native000
Asian232548
Native Hawaiian or Other Pacific Islander000
Black or African American101
White5555110
More than one race000
Unknown or Not Reported8816
Cancer Category
Cancer Category(Participants)Rogaratinib (BAY1163877)_Overall PopulationChemotherapy_Overall PopulationTotal
Location of primary cancer: bladder5645101
Location of primary cancer: Ureter171431
Location of primary cancer: Renal pelvis122840
Location of primary cancer: Proximal urethra213
Cancer stage at study entry
Cancer stage at study entry(Participants)Rogaratinib (BAY1163877)_Overall PopulationChemotherapy_Overall PopulationTotal
Stage III B134
Stage IV51217
Stage IV A132437
Stage IV B6748115
Unknown112
PIK3CA and/or RAS activating mutations
PIK3CA and/or RAS activating mutations(Participants)Rogaratinib (BAY1163877)_Overall PopulationChemotherapy_Overall PopulationTotal
Absent6569134
Present101020
Unknown12921
FGFR expression from Targos
FGFR expression from Targos(Participants)Rogaratinib (BAY1163877)_Overall PopulationChemotherapy_Overall PopulationTotal
Negative131427
Positive6969138
Not assessed5510
08

Study locations

161 sites
  • Alaska Clinical Research Center, LLC
    Anchorage, Alaska 99503, United States
  • University of Arizona Cancer Center
    Tucson, Arizona 85719, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • UC Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • Sansum Clinic
    Santa Barbara, California 93105, United States
  • Rocky Mountain Cancer Centers
    Littleton, Colorado 80120-4413, United States
  • UF Cancer Center at Orlando Health
    Orlando, Florida 32806, United States
  • University of Kansas Medical Center
    Westwood, Kansas 66205, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Compass Oncology
    Tigard, Oregon 97223, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15232, United States
  • Bon Secours St. Francis Hospital
    Greenville, South Carolina 29607, United States
  • Texas Oncology-Denton South
    Denton, Texas 76210, United States
  • Houston Methodist Hospital
    Houston, Texas 77030-2707, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Summit Cancer Center
    Spokane, Washington 99208, United States
  • Mid North Coast Cancer Institute
    Coffs Harbour, New South Wales 2450, Australia
  • Northern Cancer Institute
    St Leonards, New South Wales 2065, Australia
  • Macquarie University Hospital
    Sydney, New South Wales 2109, Australia
  • Riverina Cancer Care Centre
    Wagga Wagga, New South Wales 2650, Australia
  • Sydney Adventist Hospital
    Wahroonga, New South Wales 2076, Australia
  • Pindara Private Hospital
    Benowa, Queensland 4217, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Landesklinikum Krems
    Krems, 3500, Austria
  • Krankenhaus der Barmherzigen Brüder
    Wien, 1020, Austria
  • Universitätsklinikum AKH Wien
    Wien, 1090, Austria
  • Klinik Ottakring - Wilhelminenspital
    Wien, 1160, Austria
  • UZ Gent
    Gent, 9000, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Clinique Saint-Pierre
    Ottignies, 1340, Belgium
  • Princess Margaret Hospital-University Health Network
    Toronto, Ontario M5G 2M9, Canada
  • Sir Mortimer B. Davis Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Ottawa Hospital-General Campus
    Ottawa, K1H 8L6, Canada
  • FuJian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School
    Nanjing, Jiangsu 210008, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210009, China
  • Liaoning Cancer Hospital and Institute
    Shengyang, Liaoning 110042, China
  • Fifth Medical Center, General Hospital of the Chinese People
    Beijing, 100071, China
  • First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
  • Huadong Hospital, Affiliated to Fudan University
    Shanghai, 200040, China
  • Fakultni nemocnice Ostrava
    Ostrava, 708 52, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha 10, 10034, Czechia
  • Fakultni Thomayerova Nemocnice
    Praha 4 - Krc, 140 59, Czechia
  • Bata Hospital
    Zlin, 762 75, Czechia
  • Aarhus Universitetshospital, Skejby
    Aarhus N, 8200, Denmark
  • Herlev Hospital - Oncology Research Dept.
    Herlev, 2730, Denmark
  • Rigshospitalet
    København, 2100, Denmark
  • Docrates Klinikka
    Helsinki, 00180, Finland
  • Hopital Jean Minjoz
    Besancon, 25030, France
  • Hôpital Saint André - Bordeaux
    Bordeaux, 33000, France
  • Centre de Lutte Contre le Cancer François Baclesse
    Caen Cedex 5, 14076, France
  • Centre Jean Perrin
    Clermont Ferrand Cedex 1, 63011, France
  • Centre Oscar Lambret - Lille
    Lille Cedex, 59020, France
  • Centre Léon Bérard
    Lyon Cedex, 69008, France
  • Institut Paoli-Calmettes - Marseille
    Marseille, 13273, France
  • Cochin - Paris
    Paris, 75674, France
  • Hôpital d'Instruction des Armées Begin
    Saint Mande, 94160, France
  • Clinique Saint Anne
    Strasbourg, 67000, France
  • Centre Médico-Chirurgical Foch
    Suresnes, 92151, France
  • Eberhard-Karls-Universität Tübingen
    Tübingen, Baden-Württemberg 72076, Germany
  • Heinrich-Heine-Universität Düsseldorf
    Düsseldorf, Nordrhein-Westfalen 40225, Germany
  • Universitätsmedizin der Johannes Gutenberg Universität Mainz
    Mainz, Rheinland-Pfalz 55131, Germany
  • Prince of Wales Hospital Hong Kong
    Shatin, Hong Kong
  • MH Egeszsegugyi Kozpont
    Budapest, 1062, Hungary
  • Orszagos Onkologiai Intezet
    Budapest, 1122, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont
    Pecs, 7624, Hungary
  • Cork University Hospital
    Cork, Ireland
  • AMNCH
    Dublin, 24, Ireland
  • Rambam Health Corporation
    Haifa, 3109601, Israel
  • Hadassah Hebrew University Hospital Ein Kerem
    Jerusalem, 9112001, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Clalit Health Services Rabin Medical Center-Beilinson Campus
    Petah Tikva, 4941492, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 5266202, Israel
  • IRST Istituto Scientifico Romagnolo per studio e cura tumori
    Forlì Cesena, Emilia-Romagna 47014, Italy
  • AUSL Modena
    Modena, Emilia-Romagna 41012, Italy
  • A.O.U. di Modena - Policlinico
    Modena, Emilia-Romagna 41124, Italy
  • A.O. San Camillo-Forlanini
    Roma, Lazio 00152, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, Lazio 00168, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milano, Lombardia 20133, Italy
  • IRCCS Istituto Europeo di Oncologia s.r.l. (IEO)
    Milano, Lombardia 20141, Italy
  • ASST Grande Ospedale Metropolitano Niguarda
    Milano, Lombardia 20162, Italy
  • A.O.U. San Luigi Gonzaga
    Torino, Piemonte 10043, Italy
  • A.O.U. Pisana
    Pisa, Toscana 56126, Italy
  • A.O.U.I. Verona
    Verona, Veneto 37134, Italy
  • Nagoya University Hospital
    Nagoya, Aichi 466-8560, Japan
  • Hirosaki University Hospital
    Hirosaki, Aomori 036-8563, Japan
  • Gunma University Hospital
    Maebashi, Gunma 371-8511, Japan
  • Gunma Prefectural Cancer Center
    Ota, Gunma 373-8550, Japan
  • Sapporo Medical University Hospital
    Sapporo, Hokkaido 060-8543, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • Kobe City Medical Center General Hospital
    Kobe, Hyogo 650-0047, Japan
  • University of Tsukuba Hospital
    Tsukuba, Ibaraki 305-8576, Japan
  • Iwate Medical University Hospital
    Morioka, Iwate 028-3695, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa 236-0004, Japan
  • Kindai University Hospital
    Osakasayama, Osaka 589-8511, Japan
  • Saitama Medical University International Medical Center
    Hidaka, Saitama 350-1298, Japan
  • Nippon Medical School Hospital
    Bunkyo-ku, Tokyo 113-8603, Japan

Showing the first 100 of 161 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sternberg CN, Petrylak DP, Bellmunt J, Nishiyama H, Necchi A, Gurney H, Lee JL, van der Heijden MS, Rosenbaum E, Penel N, Pang ST, Li JR, Garcia Del Muro X, Joly F, Papai Z, Bao W, Ellinghaus P, Lu C, Sierecki M, Coppieters S, Nakajima K, Ishida TC, Quinn DI. FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. J Clin Oncol. 2023 Jan 20;41(3):629-639. doi: 10.1200/JCO.21.02303. Epub 2022 Oct 14. PubMed 36240478 ↗
  • Grunewald S, Politz O, Bender S, Heroult M, Lustig K, Thuss U, Kneip C, Kopitz C, Zopf D, Collin MP, Boemer U, Ince S, Ellinghaus P, Mumberg D, Hess-Stumpp H, Ziegelbauer K. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int J Cancer. 2019 Sep 1;145(5):1346-1357. doi: 10.1002/ijc.32224. Epub 2019 Mar 13. PubMed 30807645 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Oct 2020, 28 months.

Results were first posted in Dec 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2018
First posted
Jan 25, 2018
StartActual
May 31, 2018
Primary completionActual
Oct 27, 2020
CompletionActual
Oct 27, 2020
Results first posted
Dec 29, 2021
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03410693
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 25, 2018
Start date
May 31, 2018
Primary completion
Oct 27, 2020
Completion
Oct 27, 2020
Results posted
Dec 29, 2021
Last update
Sep 28, 2022

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rogaratinib

Start the discussion